AbbVie dumps an early-stage drug in $ 225M Alzheimer’s alliance with Alector-Endpoints News

In the depths of frigid, snowy Chicago winters, it’s wise and life-saving to wear plenty of layers when stepping outside. In a cold, bear market that has shuttered nearly every chance at entering, public biotechs are also trying to add on layers in the form of follow-on financings, because having a ticker means always being outside.

Padding the reserves with more capital is an uphill battle in a market littered with biotechs trading below cash, a slew of negative trial results and a relatively stagnant M&A path. Yet, some biotechs have been able to secure mittens, scarves and even parkas in this environment. Three more announced plans Thursday night and before Nasdaq turned on the lights Friday morning.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 145,200+ biopharma pros reading Endpoints daily – and it’s free.


Leave a Comment

Your email address will not be published.

%d bloggers like this: